A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
a study on Vitiligo
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at UC Davis UC Irvine
- Dates
- study startedcompletion around
Description
Summary
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.
Upadacitinib is an approved drug for various immune-mediated inflammatory diseases and is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B) and an optional exploratory Narrow-Band Ultraviolet B (NB-UVB) phototherapy study (Study 3). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo and 2 in 3 chance participants will receive upadacitinib. In Period B, all participants will receive upadacitinib. Approximately 270 adult and adolescent participants with NSV will be enrolled in each main study ((Study 1 and Study 2, 540 subjects total) at approximately 90 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI 90 at week 48 while on study drug, to enter Study 3.
In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 weeks. Participants will be followed up for 30 days. Study 3 participants will receive upadacitinib monotherapy or upadacitinib with NB-UBV phototherapy for at least 24 weeks followed by upadacitinib alone.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Official Title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
Keywords
Vitiligo, Non-Segmented Vitiligo, Viti-Up, Upadacitinib, NB-UVB (narrow-band ultraviolet B) Phototherapy, (Optional) Study 3:
Eligibility
You can join if…
Open to people ages 12 years and up
- Documented clinical diagnosis of non-segmented vitiligo (NSV).
- At Screening and Baseline Visits, participants must satisfy at least 1 of the following criteria:
- >= 0.5 F-VASI and 5 <= T-VASI < 50 AND have failed at least 1 topical corticosteroid and/or at least 1 topical calcineurin inhibitor for vitiligo; or
- >= 0.5 F-VASI and 5 <= T-VASI < 50 AND have a sign of actively progressing vitiligo; or
- >= 0.5 F-VASI and 10 <= T-VASI < 50.
You CAN'T join if...
- Segmental or localized vitiligo.
- History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
- >33% leukotrichia in areas of vitiligo on the face or > 33% leukotrichia in areas of vitiligo on the body (including the face).
Locations
- University of California Irvine /ID# 260080
Irvine California 92697-1385 United States - University of California Davis Health /ID# 260062
Sacramento California 95817 United States - Vitiligo & Pigmentation Institute of Southern California /ID# 259970
Los Angeles California 90036-5679 United States - Joseph Raoof Md,Inc /Id# 260055
Encino California 91436 United States - Dermatology Research Associates /ID# 260056
Los Angeles California 90045 United States - Integrative Skin Science and Research /ID# 260060
Sacramento California 95815 United States - Stanford University /ID# 260081
Redwood City California 94063 United States - Clinical Trials Research Institute /ID# 259910
Thousand Oaks California 91320-2130 United States
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- Related Info
- ID
- NCT06118411
- Phase
- Phase 3 Vitiligo Research Study
- Study Type
- Interventional
- Participants
- About 614 people participating
- Last Updated